Indeed, ceritinib, a second-generation ALK inhibitor, has demonstrated efficacy in treating ALK-positive NSCLC in patients who have acquired resistance to crizotinib [191,192]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.